The results establish that targeting Notch1-YY1-ICAM1 signaling axis may enhance immunotherapy efficacy by activating CD8<sup>+</sup> T cell-driven cancer cell pyroptosis, providing a safe and effective treatment strategy for HCC patients. Here, CD8A is linked to hepatocellular carcinoma.